FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171134602> ?p ?o ?g. }

• W2171134602 endingPage "9" @default.
• W2171134602 startingPage "3791" @default.
• W2171134602 abstract "Breast cancer is a leading cause of morbidity and mortality in women in developed countries and in increasingly developing countries. In general, estrogen receptor (ER)-positive breast cancers have a better prognosis and are often more responsive to anti-estrogen therapy. Unfortunately, ER-negative breast cancers are more aggressive and unresponsive to anti-estrogens. The aim of this investigation was to evaluate the 5-fluorouracil (5-FU) and methotrexate (MTX) combination to determine the most effective regimen considering the mechanism of action in treating ER-negative human breast cancer cells and at the same time mitigating methotrexate cytotoxicity in human bone marrow cells.In order to determine the sequence-dependent interaction between MTX and 5-FU on proliferation, cell viability was carried out using the Quick Cell Proliferation Assay by exposing the human estrogen negative (MDA-MB-436 and Hs-578T) and bone marrow (HS-5) cells to: (i) MTX and 5-FU alon; (ii) MTX 2 h prior to 5-FU (MTX/5-FU; (iii) 5-FU 2 h prior to MTX (5-FU/MTX).The growth rate in MDA-MB-436 was 23.5 +/- 3.98%, in Hs-578T 30 +/- 5.9% and HS-5 32 +/- 3.1% of the control for MTX/5-FU. Whereas the growth rate in MDA-MB-436 was 28.5 +/- 4.1%, in Hs-578T 34.7 +/- 3.5% and HS-5 68.6 +/- 6.3% of the control for 5-FU/MTX combinations. The later combination exhibits significant protection against MTX cytotoxicity in bone marrow and at same time maintained maximum cytotoxicity in estrogen negative breast cancer cell lines. The findings were further supported by cell flow cytometry, apoptosis and Western blot analysis data.The combination of 5-FU/MTX effectively maintains the maximum inhibitory effect of MTX in ER-negative breast cancer and protects against MTX cytotoxicity in human bone marrow." @default.
• W2171134602 created "2016-06-24" @default.
• W2171134602 creator A5022713049 @default.
• W2171134602 creator A5037018257 @default.
• W2171134602 creator A5042203775 @default.
• W2171134602 creator A5046176824 @default.
• W2171134602 creator A5051677321 @default.
• W2171134602 creator A5074800064 @default.
• W2171134602 date "2008-01-30" @default.
• W2171134602 modified "2023-09-27" @default.
• W2171134602 title "Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow." @default.
• W2171134602 cites W1862101204 @default.
• W2171134602 cites W1961026612 @default.
• W2171134602 cites W1985436963 @default.
• W2171134602 cites W1989069744 @default.
• W2171134602 cites W1994610843 @default.
• W2171134602 cites W2003098361 @default.
• W2171134602 cites W2010397777 @default.
• W2171134602 cites W2016122643 @default.
• W2171134602 cites W2017352677 @default.
• W2171134602 cites W2037790468 @default.
• W2171134602 cites W2039658833 @default.
• W2171134602 cites W2058471639 @default.
• W2171134602 cites W2072515215 @default.
• W2171134602 cites W2083791611 @default.
• W2171134602 cites W2123613739 @default.
• W2171134602 cites W2130969312 @default.
• W2171134602 cites W2403952550 @default.
• W2171134602 cites W33253094 @default.
• W2171134602 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18225534" @default.
• W2171134602 hasPublicationYear "2008" @default.
• W2171134602 type Work @default.
• W2171134602 sameAs 2171134602 @default.
• W2171134602 citedByCount "1" @default.
• W2171134602 countsByYear W21711346022021 @default.
• W2171134602 crossrefType "journal-article" @default.
• W2171134602 hasAuthorship W2171134602A5022713049 @default.
• W2171134602 hasAuthorship W2171134602A5037018257 @default.
• W2171134602 hasAuthorship W2171134602A5042203775 @default.
• W2171134602 hasAuthorship W2171134602A5046176824 @default.
• W2171134602 hasAuthorship W2171134602A5051677321 @default.
• W2171134602 hasAuthorship W2171134602A5074800064 @default.
• W2171134602 hasConcept C109316439 @default.
• W2171134602 hasConcept C121608353 @default.
• W2171134602 hasConcept C126322002 @default.
• W2171134602 hasConcept C143998085 @default.
• W2171134602 hasConcept C202751555 @default.
• W2171134602 hasConcept C2776694085 @default.
• W2171134602 hasConcept C2776999253 @default.
• W2171134602 hasConcept C2777164284 @default.
• W2171134602 hasConcept C2777760704 @default.
• W2171134602 hasConcept C2778397455 @default.
• W2171134602 hasConcept C2780007613 @default.
• W2171134602 hasConcept C2780456651 @default.
• W2171134602 hasConcept C2781059491 @default.
• W2171134602 hasConcept C502942594 @default.
• W2171134602 hasConcept C530470458 @default.
• W2171134602 hasConcept C55493867 @default.
• W2171134602 hasConcept C71924100 @default.
• W2171134602 hasConcept C84606932 @default.
• W2171134602 hasConcept C86803240 @default.
• W2171134602 hasConcept C98274493 @default.
• W2171134602 hasConceptScore W2171134602C109316439 @default.
• W2171134602 hasConceptScore W2171134602C121608353 @default.
• W2171134602 hasConceptScore W2171134602C126322002 @default.
• W2171134602 hasConceptScore W2171134602C143998085 @default.
• W2171134602 hasConceptScore W2171134602C202751555 @default.
• W2171134602 hasConceptScore W2171134602C2776694085 @default.
• W2171134602 hasConceptScore W2171134602C2776999253 @default.
• W2171134602 hasConceptScore W2171134602C2777164284 @default.
• W2171134602 hasConceptScore W2171134602C2777760704 @default.
• W2171134602 hasConceptScore W2171134602C2778397455 @default.
• W2171134602 hasConceptScore W2171134602C2780007613 @default.
• W2171134602 hasConceptScore W2171134602C2780456651 @default.
• W2171134602 hasConceptScore W2171134602C2781059491 @default.
• W2171134602 hasConceptScore W2171134602C502942594 @default.
• W2171134602 hasConceptScore W2171134602C530470458 @default.
• W2171134602 hasConceptScore W2171134602C55493867 @default.
• W2171134602 hasConceptScore W2171134602C71924100 @default.
• W2171134602 hasConceptScore W2171134602C84606932 @default.
• W2171134602 hasConceptScore W2171134602C86803240 @default.
• W2171134602 hasConceptScore W2171134602C98274493 @default.
• W2171134602 hasIssue "6B" @default.
• W2171134602 hasLocation W21711346021 @default.
• W2171134602 hasOpenAccess W2171134602 @default.
• W2171134602 hasPrimaryLocation W21711346021 @default.
• W2171134602 hasRelatedWork W1524793778 @default.
• W2171134602 hasRelatedWork W1647553833 @default.
• W2171134602 hasRelatedWork W1862101204 @default.
• W2171134602 hasRelatedWork W189562276 @default.
• W2171134602 hasRelatedWork W1977553393 @default.
• W2171134602 hasRelatedWork W1990160392 @default.
• W2171134602 hasRelatedWork W2001578335 @default.
• W2171134602 hasRelatedWork W2004086439 @default.
• W2171134602 hasRelatedWork W2014467256 @default.
• W2171134602 hasRelatedWork W2036467757 @default.
• W2171134602 hasRelatedWork W2047700777 @default.
• W2171134602 hasRelatedWork W2060418938 @default.

• next